Compliance professionals from more than 200 life sciences companies gathered in Washington, D.C., for the 2019 CBI Pharmaceutical Compliance Congress (PCC). Bryant Aaron, chief compliance officer at Novartis Pharmaceutical Corp., opened the conference by reminding attendees that the compliance function helps companies navigate changing regulations, enabling organizations to deliver critical treatments to patients. Aaron also emphasized that “our industry grows together and we all benefit from each other’s successes.”
Conference discussions focused on empowering the compliance function, insights from recent enforcement actions, and a look at new and upcoming laws.
Empowering the compliance function was a recurring theme of PCC this year. Key tips included:
Given the flurry of recent False Claims Act settlements related to copay assistance foundations (including corporate integrity agreements for three new CIAs in the past month), it is no surprise that patient programs and support services were a hot topic at PCC. Takeaways from relevant sessions include: